Valuation dashboard for NeuroSense Therapeutics Ltd. (NRSN) with P/E N/A, P/B -5.76, EV/EBITDA -1.12 and dividend yield 0.00%. DCF, Graham Number and Earnings Power Value models plus sector comparison against other Healthcare companies.
NeuroSense Therapeutics Ltd. operates as a biotechnology firm in the clinical development phase, committed to discovering and developing effective therapies for individuals suffering from severe neurodegenerative conditions. The company's leading drug candidate, PrimeC, is an innovative oral formulation that has successfully concluded Phase IIa clinical investigations for the management of amyotrophic lateral sclerosis (ALS).
Analysis Summary
Trailing-twelve-month margins: gross margin 0.0%, operating margin 0.0%, net margin 0.0%.
At the current price of $6.49, NRSN has negative trailing earnings (P/E not meaningful) and an ROE of 10.70%. Market capitalisation stands at $11M.
Balance sheet quality for NRSN: current ratio of 0.3. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | -5.76 |
| EV / EBITDA | -1.12 |
| Dividend Yield | 0.00% |
Valuation Models
| DCF Fair Value | $-0.54 |
| vs Current Price | -108.3% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| NRSN | NeuroSense Therapeutics Ltd. | $11M | 10.7% | ||
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $131.8B | |||
| VRTX | Vertex Pharmaceuticals Incorporated | $130.3B | 29.68 | 6.45 | 23.3% |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $84.0B | |||
| REGN | Regeneron Pharmaceuticals, Inc. | $79.8B | 18.79 | 2.57 | 13.8% |
| ARGX | argenx SE | $61.2B | 36.30 | 7.40 | 21.7% |
| MRNA | Moderna, Inc. | $57.8B | 1.34 | -39.2% | |
| RVMD | Revolution Medicines, Inc. | $41.7B | 15.96 | -96.4% |
Price
| Price | $6.49 |
| Market Cap | $11M |
| Exchange | NASDAQ |
| Country | IL |
Profitability
| Return on Equity | 1070.23% |
| Return on Invested Capital | 797.48% |
| Return on Assets | -1082.20% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: CLGN · CVKD · ENLV · KLTO · NERV · NRXS · RLYB
Explore sector: Healthcare · Biotechnology
More sections of NRSN: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks